response to controlled ovarian stimulation. In vitro fertilization
Conditions
Interventions
Intervention 1: In the agonist group on cycle day 21, Busereline acetate was started as 0.5 mg daily (S.C.) injection until menstruation had begun. At day 3 of next menstrual cycle, the dose of Busere
Treatment - Drugs
In the agonist group on cycle day 21, Busereline acetate was started as 0.5 mg daily (S.C.) injection until menstruation had begun. At day 3 of next menstrual cycle, the dose of Busereline was diminis
In the antagonist group rFSH treatment was begun on day 3 of menstrual cycle and the dose was adjusted on the basis of follicle graph using Gonal-F and HMG When there was one follicle 14mm in diameter
Sponsors
Tehran Univercity of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 38 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age <38 years; normal basal serum FSH; 20 = BMI <30 kg/m2; regular menstrual cycle. Exclusion criteria: Polycystic ovary syndrome; severe endometriosis; history of poor response in previous treatment cycles; history of repeated IVF failure more than 3 cycles failed.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pregnancy. Timepoint: after one cycle of controlled ovarian stimulation. Method of measurement: chemical, clinical and ongoing pregnancy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of retrieved oocytes. Timepoint: after one cycle of controlled ovarian stimulation. Method of measurement: counting by light microscope. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mina Jafarabadi
Reproductive Health Research Center, Tehran University of Medical Sciences
Outcome results
None listed